Exposure to satralizumab in AQP4-positive NMOSD during pregnancy: A case report and review of the literature

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease of the central nervous system. It mainly affects young women and can lead to serious episodes involving the spinal cord and optic nerves. Treatments, may pose risks to the fetus, with limited safety data available. Satralizumab, is effective in reducing relapse rates but lacks sufficient safety data for use during pregnancy. The case of a 32-year-old woman with NMOSD who was treated with satralizumab during her first trimester is presented. This case provides preliminary evidence on satralizumab use in pregnancy, suggesting it might be a viable option with careful management.